Pancreatic Cancer Research

ResearcherColumbia UniversityActive in the last 2 years

Tito Fojo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-8083-2688; OpenAlex author ID A5006092876. Sources: OpenAlex.

Their work

Papers
7 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
27
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: none · 2025: none · 2026: 3 papers

Papers 7

  1. Combined HDAC and eIF4A inhibition: A novel epigenetic therapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.drup.2025.101312↗
  2. Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study with single-cell correlatives. Co-author DOI 10.1038/s41467-026-76559-4↗
  3. Impact of β-Blockers, Statins, and Cholinergic Agents on Clinical Outcomes in Pancreatic Cancer: A Retrospective VA Cohort Study. Co-author DOI 10.1158/1055-9965.epi-26-0062↗
  4. Tumor Growth Rate Informs Treatment Efficacy in Metastatic Pancreatic Adenocarcinoma: Application of a Growth and Regression Model to Pivotal Trial and Real-Wo… Co-author DOI 10.1093/oncolo/oyac217↗
  5. Gemcitabine plus nab-paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evaluation of tumor growth in Veterans. Co-author DOI 10.1053/j.seminoncol.2021.02.001↗
  6. Clinical trials: New drug for pancreatic cancer highlights the dual effect of regulatory approvals. First author DOI 10.1038/nrclinonc.2016.22↗
  7. Targeting KRAS and the vitamin D receptor via microtubules Last author DOI 10.1038/nrclinonc.2015.125↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Susan Elaine Bates · 7 shared papers, 2015–2026 · strength 1.23
  2. Keith Magnus Sigel · 3 shared papers, 2021–2026 · strength 0.59
  3. Kenneth P. Olive · 2 shared papers, 2026 · strength 0.42
  4. John A. Chabot · 2 shared papers, 2023–2026 · strength 0.34
  5. Gulam Abbas Manji · 2 shared papers, 2023–2026 · strength 0.34
  6. Ruth Aroon White · 1 shared paper, 2026 · strength 0.33
  7. Jason Cham · 1 shared paper, 2026 · strength 0.33
  8. Jiheum Park · 1 shared paper, 2026 · strength 0.33
  9. Agnès Basseville · 2 shared papers, 2015–2026 · strength 0.32
  10. Thierry Conroy · 2 shared papers, 2021–2023 · strength 0.26
  11. Celine Yeh · 2 shared papers, 2021–2023 · strength 0.26
  12. Ravikanth Maddipati · 1 shared paper, 2026 · strength 0.23
  13. Maryam Safari · 1 shared paper, 2026 · strength 0.23
  14. Alina Cornelia Iuga · 1 shared paper, 2026 · strength 0.19
  15. Michael S. May · 1 shared paper, 2026 · strength 0.19
  16. Alexander Grenander Raufi · 1 shared paper, 2026 · strength 0.19
  17. Linda Y. Wu · 1 shared paper, 2026 · strength 0.19
  18. Li Li · 1 shared paper, 2026 · strength 0.19
  19. Benjamin Izar · 1 shared paper, 2026 · strength 0.19
  20. Michael D. Kluger · 1 shared paper, 2026 · strength 0.19
  21. Beth Schrope · 1 shared paper, 2026 · strength 0.19
  22. Yvonne M. Saenger · 1 shared paper, 2023 · strength 0.15
  23. Marc Ychou · 1 shared paper, 2023 · strength 0.15
  24. Gayle Jameson · 1 shared paper, 2023 · strength 0.15
  25. Rachael Ann Safyan · 1 shared paper, 2023 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.